Tumour-derived CSF2/granulocyte macrophage colony stimulating factor controls myeloid cell accumulation and progression of gliomas by Sielska, M. et al.
ARTICLE
Cellular and Molecular Biology
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BACKGROUND: Malignant tumours release factors, which attract myeloid cells and induce their polarisation to pro-invasive,
immunosuppressive phenotypes. Brain-resident microglia and peripheral macrophages accumulate in the tumour
microenvironment of glioblastoma (GBM) and induce immunosuppression fostering tumour progression. Macrophage colony
stimulating factors (CSFs) control the recruitment of myeloid cells during peripheral cancer progression, but it is disputable, which
CSFs drive their accumulation in gliomas.
METHODS: The expression of CSF2 (encoding granulocyte-macrophage colony stimulating factor) was determined in TCGA
datasets and five human glioma cell lines. Effects of stable CSF2 knockdown in glioma cells or neutralising CSF2 or receptor CSF2Rα
antibodies on glioma invasion were tested in vitro and in vivo.
RESULTS: CSF2 knockdown or blockade of its signalling reduced microglia-dependent glioma invasion in microglia-glioma co-
cultures. CSF2-deficient human glioma cells encapsulated in cell-impermeable hollow fibres and transplanted to mouse brains,
failed to attract microglia, but stimulated astrocyte recruitment. CSF2-depleted gliomas were smaller, attracted less microglia and
macrophages, and provided survival benefit in tumour-bearing mice. Apoptotic microglia/macrophages were detected in CSF2-
depleted tumours.
CONCLUSIONS: CSF2 is overexpressed in a subset of mesenchymal GBMs in association with high immune gene expression.
Tumour-derived CSF2 attracts, supports survival and induces pro-tumorigenic polarisation of microglia and macrophages.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0862-2
BACKGROUND
Glioblastoma (GBM) is a diffusive and highly malignant brain
tumour, which is heavily infiltrated with brain-resident microglia,
peripheral macrophages, granulocytes, and myeloid-derived
suppressive cells (reviewed by refs. 1–3). Tumour-derived mole-
cules act as attractants and functionally polarise infiltrating cells,
so they promote extracellular matrix remodelling, support tumour
invasion and angiogenesis, and contribute to local and systemic
immunosuppression.4–9 Genetic or pharmacological depletion of
microglia leads to reduction of glioma progression emphasising
the importance of tumour–microglia interactions.5,7,10–12 Tumour-
secreted factors that mediate communication of glioma with
microglia and infiltrating myeloid cells could be attractive
therapeutic targets in glioblastoma.
Signals for immune cell recruitment in GBM, identities of
infiltrating populations and their contribution to tumour progres-
sion, are disputable. Macrophage colony stimulating factor (M-CSF,
CSF1) and granulocyte macrophages colony stimulating factor
(GMCSF, CSF2) are main factors that regulate proliferation and
differentiation of myeloid cells.13,14 CSF1 signalling was implicated in
glioma invasion, as a blockade of CSF-1R affected functions of
CD11b+ cells (microglia/macrophages), along with glioma invasion
in vitro and in vivo.15,16 CSF-1R inhibitor BLZ945 reduced tumour
growth, without affecting the number of infiltrating CD11b+ cells
(possibly due to compensation by glioma-secreted CSF2 and
interferon γ) but reduced the pro-invasive markers in CD11b+
cells.16,17 Another CSF-1R inhibitor PLX3397 supressed glioma cell
proliferation and tumour growth and interfered with polarisation of
immune cells.18
CSF2 (granulocyte macrophage colony stimulating factor)
stimulates survival, proliferation and differentiation of hemato-
poietic myeloid cells.19,20 Several in vitro studies implicated CSF2
produced by cancer cells in the autocrine regulation of growth of
human melanoma, prostate, bladder, gastric colon, skin and non-
small-cell lung cancer cells.21–25 CSF2 and its receptor CSF2R are
co-expressed in human glioma cell lines and GBMs.26–30 Secreted
CSF2 stimulates glioma cell growth and invasion26 but its
influence on GBM microenvironment has not been thoroughly
explored. We previously reported that Csf2 produced by murine
GL261 glioma cells supports microglia-dependent glioma invasion
in vitro and tumour growth in mice.6
In the present study, we aimed to investigate the role of glioma-
secreted CSF2 in controlling glioma–microglia interactions in vitro
and in animal models. We demonstrate that depletion of CSF2 in
www.nature.com/bjc
Received: 26 July 2019 Revised: 19 March 2020 Accepted: 6 April 2020
1Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland and 2Max Delbruck Center, Molecular Neurosciences, Berlin-Buch, Germany
Correspondence: Bozena Kaminska (b.kaminska@nencki.edu.pl)
© The Author(s), under exclusive licence to Cancer Research UK 2020
two human glioma cell lines reduces microglia-dependent glioma
invasion in vitro and affects pro-tumorigenic polarisation of
microglia. CSF2 knockdown in glioma cells results in impaired
recruitment of microglia and macrophages in vivo, reduced
glioma growth in mice and improved animal survival.
METHODS
CFS2 and immune gene expression in gliomas in the TCGA dataset
Data from five normal brain samples, 248 WHO grade II, 261 WHO
grade III and 160 WHO grade IV tumour samples were acquired
from TCGA RNAseq repository as data level 3 (FPKM values),
quantile normalised and log2 transformed. The CSF2 expression in
normal brain tissues and gliomas of different WHO grades and
within molecular subtypes of glioblastoma was compared. More-
over, glioma samples from TCGA dataset were separated into two
groups, one with no CSF2 expression (FPKM= 0) and the other
with detectable CSF2 expression (FPKM > 0.05). Statistical analysis
and functional analysis were performed in these two groups (Gene
Ontology analysis using clusterProfiler R package).
Cell cultures
Human glioblastoma cell lines: LN18, LN229, T98G, U251, U87
(ATCC, Manassas, VA) were cultured in DMEM supplemented with
10% foetal bovine serum (FBS, Gibco, MD, USA) and antibiotics
(100 U/mL penicillin, 100 μg/mL streptomycin). Jurkat leukaemic T-
cell lymphoblast were cultured in RPMI 1640 with 2 mM
Glutamine, 10% FBS and antibiotics. Mouse microglia BV2 cell
line (ATCC, Manassas, VA) was cultured in DMEM glutaMAX
supplemented with 2% FBS and antibiotics. Human immortalised
microglia cell line (HM SV40) (Applied Biological Materials Inc.) was
cultured in Prigrow III medium (Applied Biological Materials Inc.)
supplemented with 10% FBS and antibiotics on extracellular
matrix pre-coated flasks. Human astrocytes (Lonza) were grown in
Astrocyte Growth Medium (Lonza). Cryopreserved human micro-
glia (1.5 × 106 cells) was purchased (3H Biomedical, Uppsala,
Sweden) and grown in Microglia Culture Medium (3H Biomedical)
with antibiotics. All cells were cultured in CO2/air (5%/95%) at 37 °
C (Heraeus, Hanau, Germany).
Development of stably transfected clones expressing shRNAs
To interfere with the CSF2 expression two complementary
oligonucleotides encoding CSF2 shRNA with BamH1 and HindIII
overhangs were designed: 5′- GATCCAAAGAGAACCTGAAGGA
CTTTTCAAGAGAAAGTCCTTCAGGTTCTCTTTGTTTTTTGGAAA-3′ and
5′- AGCTTTTCCAAAAAACAAAGAGAACCTGAAGGACTTTCTCTTGAA
AAGTCCTTCAGGTTCTCTTTG -3′. The annealed DNA was ligated
into the pSilencer 2.0-U6 vector (Ambion, Austin, TX), linearised
with BamH1 and HindIII enzymes. The resulting plasmid (shCSF2)
was sequenced. pSilencer 2.0-U6 Negative Control (Ambion,
Austin, TX) was used as a control (shNeg). U87 and LN18 glioma
cells were electroporated with 1.0 µg of plasmid DNA using Amaxa
Cell Line Nucleofector Kit (Lonza). The following day, the medium
was changed to a complete medium containing hygromycin B (50
µg/ml for U87; 200 µg/ml for LN18). Resistant clones (shCSF2 or
shNeg) were selected after 2 weeks and analysed for the
expression of CSF2 mRNA using quantitative PCR (qPCR).
Quantification of mRNA and protein levels
RNA was isolated using RNeasy kit (Qiagen) and RNA quality/yield
was verified using Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA). Two independent samples of total RNA from non-
tumoural human brains pooled from multiple donors were
purchased from Ambion and Clontech, and served as control,
normal brain samples. The cDNA was synthesised by extension of
the oligo(dT)15 primers (2.5 mmol/L) using 200 units of M-MLV
reverse transcriptase (Sigma-Aldrich, Germany). The qPCR ampli-
fication was performed with SYBR Green PCR mix in the following
conditions: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 15 s
at 95 °C and 1min at 60 °C using a 7900HT PCR System (Life
Technologies). The following primer sequences were used: 5′-
ACCTGCCTACAGACCCGCCT-3′ and 5′-GAAGTTTCCGGGG
TTGGAGGGC-3′ for human CSF2; 5′-CGGACATCTAAGGGCATCA
ACA-3′ and 5′-AACGAACGAGACTCTGGCATG-3′ for 18S RNA. The
relative quantification of gene expression was determined using
the comparative CT method. The expression levels were compared
with that of 18S RNA. Gene expression in primary cultures of
human microglial cells was measured using TaqMan Gene
Expression Assays (Life Technologies, Carlsbad, CA). Specific
primers and FAM-labelled probe sets for IL10 (Hs00961622_m1),
MYC (Hs00153408_m1), IRF7 (Hs01014809_g1) and IL1B
(Hs01555410_m1), GAPDH (Hs02758991_g1) were used. The
reaction consisted of cDNA equivalent to 50 ng RNA, 5 µl Fast
TaqMan PCR master mix (Life Technologies, Carlsbad, CA) and 0.5
µl of each primer. Thermal cycling conditions: 10min at 95 °C and
40 cycles of 95 °C for 15 s and 1min at 60 °C were employed for
annealing and extension.
To determine CSF2 production, human glioma cells and human
astrocytes (1 × 106 cells) were seeded on the plates, incubated
overnight, then culture conditioned media were collected and
analysed by ELISA (Abcam, ab100529).
Cell survival and proliferation assays
U87 and LN18 glioma cells were cultured in 24-well plates for 24,
48 or 72 h. Cells were incubated with MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, Sigma, 0.5 mg/ml) for 3 h
and then lysed with a buffer containing 20% SDS and 50% DMF.
Cell proliferation was determined using Cell Proliferation ELISA
BrdU assay (Roche Diagnostics GmbH, Germany). Briefly, 1.5 × 104
U87 and LN18 glioma cells were seeded onto 96-well plates
overnight and then incubated with 10 µM BrdU (5-bromo-2′-
deoxyuridine) for 2 h, washed intensively, and fixed. Quantification
of incorporated BrdU was performed according to manufacturer’s
protocol. Optical densities in MTT or BrdU assays were measured
at 570 or 450 nm, respectively, using a scanning multi-well
spectrophotometer (Thermo Labsystem Multiscan EX).
Invasion assay
Invasion assay was performed as described.5 Briefly, 24-well cell
culture inserts (12 μm pore size Millicell, Millpore, Tullagreen, Ireland)
were coated with 1mg/mL Growth Factor Reduced Matrigel Matrix
(BD Biosciences, CA, USA) in DMEM, and dried at 37 °C for 5 h. LN18
and U87 glioma cells were seeded at 2 × 104 on matrigel-covered
membrane in an upper compartment and then inserts were
transferred to a 24-well plate with or without human SV40 microglial
cells (HM SV40), murine primary microglia cultures or BV2 cells in a
lower compartment. After 18 h cells invading through the matrigel
were fixed with 95% methanol and stained with DAPI (4′,6-
Diamidino-2-Phenylindole; 0.01mg/ml, Sigma). The membranes
from inserts were cut out and invading cells were counted using
Laser Scanning Cytometry (LSC, CompuCyte). In some experiments,
images were acquired using fluorescence microscope (Leica
DM4000B, ×10 objective) from five independent fields and numbers
of cell nuclei were counted using ImageJ software.
For studies with neutralising anti-CSF2 or anti-CSF2Rα anti-
bodies, mouse BV2 microglial cells or human SV40 microglia were
plated onto 24-well plates at the density of 4 × 104. After 24 h, the
culture medium was replaced with fresh one containing Ab CSF2
(500 ng/mL, ABCAM, #ab9667), Ab CSFRα (20 ng/mL, PE Mouse
Anti-Human CD116, BD Pharmingen™, #551373) or isoAb CSF2R
(20 ng/mL, PE Mouse IgG1, κ Isotype Control, BD Pharmingen™,
#556650), 1 h before seeding glioma cells onto inserts.
Cell encapsulation and hollow fibre inoculation
C57BL/6 (8–10 weeks) mice were handled according to govern-
mental (LAGeSo) and internal (Max Delbruck Center, Germany)
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rules and regulations. Environmental conditions were as follows:
temperature of 21 °C ± 2 °C, humidity of 55% ±10%, a standard
12∶12 light:dark cycle. Animals were housed in standard cages
and given free access to food and water ad libitum. Mice were
anesthetised with i.p. injections of 10 µl of the anaesthetic mixture
(containing 0.1% xylazyne and 1.5% ketamine-hydrochloride
mixture in 0.9% NaCl_per body weight. The eyes of mice were
covered with glycerine fat to avoid cornea drying. Choice of
anaesthetics, dosage and way of delivery was according to
guidelines of the Local Ethics Committee.
Human LN18 and U87 glioma cells expressing shNeg or shCSF2
(2 × 106 cells/ml) were infused into hollow fibres (HF) (Minntech,
Minneapolis, USA). Fibres were cut into 5 mm length pieces and
sealed at both ends. Cell number in the fibre was determined and
only fibres with an equal number of cells were used. The mouse
head was placed onto a stereotactic frame (David Kopf
Instruments, Tujunga, USA) under anaesthesia. Through a midline
incision, a burr hole was drilled at 1 mm anterior to the bregma
and 1.5 mm both right and left side from the midline. Canals were
created by inserting a 26-gauge Hamilton syringe 5mm ventral
from dura mater. Then the HFs were inserted into both canals.
After completing the experiment, the animals were anesthe-
tised with an i.p. injection of ketamine (75 mg/kg) and medeto-
midine (1 mg/kg) and after verification of the unresponsiveness to
the noxious stimuli and absent reflexes, mice were transcardially
perfused with PBS and 4% paraformaldehyde. Mice were sacrificed
and brains were removed and post-fixed for 24 h and placed in
30% sucrose in PBS at 4 °C. Subsequently, the brains were frozen
using dry CO2 and serial 20-µm-thick coronal sections were
collected and stained with toluidine blue.
Intracranial glioma implantation and quantification of tumour size
The animal study was conducted according to the protocol
approved by the Local Ethics Committee (259/2012). Experiments
were performed on BALB/c Nude Mouse (CAnN.Cg-Foxn1nu/Crl
from Charles River Laboratories, USA), housed in individually
ventilated home cages (IVC) in a pathogen free environment. Mice
were fed with standard chow ad libitum and kept under standard
day/night conditions. Ten weeks old male mice were anesthetised
with isoflurane inhalant anaesthesia (4–5% induction, 1–2%
maintenance, 21% oxygen) using Isoflurane vaporiser (Temsega,
Tabletop Anesthesia Station), and analgesic Butorphanol (1 mg/kg,
ip.; Orionvet) and Tolfedine 4% (4mg/kg s.c.; Vetoquinol) was
given as a single injection. Before starting the surgical procedure
and during the surgery the depth of anaesthesia was verified by
the lack of deep pain response in the limb and breathing
regularity. Choice of specific anaesthetics was recommended by
the veterinarian and approved by The Local Ethics Committee.
After performing a 1 cm longitudinal skin incision at the level of
sagittal suture, 2 mm diameter hole was drilled with a micromotor
drill (Stoelting) according to the coordinates (1.5 mm AP, 1.5 mm
ML). LN18 glioma cells expressing shCSF2 or shNeg (1 × 106 cells in
3 µl of DMEM) were implanted under sterile conditions into the
right striatum using 1ml syringe with a 26-gauge needle in a
stereotactic apparatus (Stoelting Co., USA). At day 15th after
glioma implantation, the animals were anesthetised with an i.p.
injection of ketamine (75 mg/kg) and medetomidine (1 mg/kg)
and after verification of the unresponsiveness to the noxious
stimuli and absent reflexes, mice were transcardially perfused with
PBS and 4% paraformaldehyde . Mice were sacrificed and brains
were removed and post-fixed for 24 h and placed in 30% sucrose
in PBS at 4 °C. Subsequently, the brains were frozen using dry CO2
and serial 20-µm-thick coronal sections were collected and stained
with toluidine blue. Images were acquired using a Leica DM4000B
microscope. Tumour areas were measured using Leica DM4000B
software on every fourth brain slice and tumour volumes were
calculated as described.7 For survival experiments the weight of
the mice with implanted cells was monitored daily and death was
recorded.
Immunofluorescence staining and TUNEL labelling
To detect microglia/macrophages, brain sections were incubated
with 10% donkey serum with PBS-0.1% Triton X-100 (PBS-T) for 30
min at room temperature (RT), then stained with a rabbit anti-Iba1
antibody (WAKO, 1:1000) for 24 h at 4 °C followed by incubation
with donkey anti-rabbit Alexa Fluor 568 (1:1000, Invitrogen) for 2 h
at RT. To visualise astrocytes and microglia, sections were blocked
with 5% BSA and 5% donkey serum for 1 h at RT, then stained with
the goat anti-Iba1 antibody (Abcam, 1:350) and with the rabbit
anti-GFAP (1:1000, Sigma) for 24 h at 4 °C followed by incubation
with donkey anti-goat Alexa Fluor 488 (1:1000, Invitrogen) and
donkey anti-rabbit Alexa Fluor 555 (1:1000, Invitrogen) for 2 h at
RT. Human cells were detected with anti-PCNA antibody (1:500,
Sigma). Cell nuclei were counterstained with DAPI (Sigma-Aldrich,
1:1000). Primary antibody was omitted in a negative control.
Sections were mounted with Fluorescent Mounting Medium
(DAKO) and images were collected using a Leica DM 4000B
microscope. Numbers of Iba1+ and GFAP+ cells were determined
using ImageJ software (NIH) in each animal.
For double Iba1+ and TUNEL staining, frozen brain slices were
treated with 99% ethanol and 80% acetic acid (2:1) at +4 °C for 30
min. Slices were first incubated for 1 h in a blocking solution: 2%
BSA+ 1.5% NGS in 0.1% PBS-T, and next with an anti-Iba1
antibody conjugated to Alexa Fluor 647 (diluted 1:1000 Invitrogen)
for 2–3 h in RT. Slices were washed three times in PBS and
incubated with TUNEL reaction mixture (Roche, In situ cell death
detection kit, fluorescein labelled) for 1 h in 37 °C. Incubation was
followed by rinsing three times in PBS, dehydration in alcohol and
mounting with DPX Mountant for histology (Fluka). Cover slipped
brain sections were examined under a fluorescent Olympus IX70
microscope and inverted confocal microscope (DM IRE2, Leica).
Statistical analysis
All data are presented as mean ± standard deviation (s.d.).
Differences between groups were evaluated using one-tailed
sample t-test (for two groups) and ANOVA (for multi-variant
comparisons). In animal experiments p value was calculated using
the Mann–Whitney U test, or Student’s t-test using Statistica
software (ver. 7.1 StatSoft. Inc, OK, USA) or GraphPad Prism v6.01
(GraphPad Software, Inc., San Diego, CA, USA).
RESULTS
CSF2 is highly expressed in a subset of mesenchymal
glioblastomas and cultured human glioma cells
First, we compared the expression of CSF2 in human gliomas of
different WHO grades and glioblastoma subtypes. All data,
including the control samples (normal brain samples) were
downloaded from the TCGA repository (The Cancer Genome Atlas
Research Network, 2008). TCGA contains a limited number of
normal brain samples, therefore only five samples were used as a
reference to show a basal level of CSF2. The highest CSF2
expression was found in a subset of patients with GBMs (Fig. 1a).
We also checked the distribution of CSF2 in different molecular
subtypes of GBMs defined by the TCGA network.31 When
compared with other subtypes, CSF2 was significantly upregulated
in the mesenchymal subtype of GBM (Fig. 1b). Furthermore, using
computational analysis with GO annotations, we identified
functional groups among genes significantly enriched (adjusted
p-value < 0.01) in gliomas with high CSF2 expression (FPKM > 0.05)
relative to tumour samples with no CSF2 expression (FPKM= 0).
We found over-representation of genes related to immune and
stress responses, defence mechanism and leucocyte activation as
the most relevant to increased CSF2 expression (Fig. 1c).
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Further, we determined the levels of CSF2 mRNA using
quantitative PCR and its protein by ELISA in five glioblastoma cell
lines, normal brain samples and normal human astrocytes (NHA). In
comparison to normal brain or NHA, the levels of CSF2 mRNA
(Fig. 1d) were upregulated in human LN18, LN229, T98, U251 and
U87 glioma cells. Concordantly, the levels of CSF2 protein
measured by ELISA were increased in culture supernatants of all
tested human glioma cells (Fig. 1e). LN18 and U87 glioma cells
showed the highest levels of CSF2 mRNA and produced abundant
quantities of CSF2 protein, therefore these cells were employed for
further experiments.
Knockdown of CSF2 in glioma cells reduces microglia-dependent
invasion and induces a shift of microglia phenotype
Using RNA interference, we generated LN18 and U87 glioma cells
stably depleted of CSF2 and for each glioma cell line we selected
two clones (shCsf2) with the highest reduction of CSF2 mRNA and
CSF2 protein levels, as determined by qPCR (Fig. 2a, c) and ELISA
(Fig. 2b, d), respectively. Control cells stably transfected with a
non-targeting shRNA (ShNeg) expressed similar levels of CSF2 as
parental cells. Silencing of CSF2 expression in LN18 and U87
glioma cells did not significantly affect cell proliferation and
survival, as demonstrated by BrdU incorporation (Fig. 2e, g) and
MTT metabolism tests (Fig. 2f, h), respectively.
Glioma cells become more invasive upon co-culture with
microglial cells.32 To study if tumour-derived CSF2 contributes to
microglia-dependent invasion, we co-cultured human glioma cells
with microglial cells and tested their invasion through a
reconstituted basement membrane matrix (Matrigel). Invasion of
glioma cells was significantly increased in the presence of both
primary microglia cultures and immortalised BV2 microglial cells
(Fig. S1), therefore further studies were performed using easily
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obtainable BV2 microglial cells. Migrating glioma cells were
quantified using laser scanning cytometry (Fig. 3a). Knockdown
of CSF2 in LN18 (Fig. 3b) and U87 (Fig. 3c) glioma cells strongly
reduced BV2-dependent invasion as compared to shNeg controls.
Similar effects were observed in the co-culture with immortalised
human SV40 microglia (HM SV40), i.e. HM SV40-stimulated
invasion was decreased in CSF2-depleted glioma cultures (Fig. 3d).
Moreover, to confirm the role of CSF2 signalling in microglia-
dependent glioma invasion, we employed neutralising antibodies
against CSF2 or its receptor CSF2Rα (Fig. 3e). Anti-CSF2 antibody
significantly reduced the stimulating activity of human SV40
microglial cells on glioma invasion and to a lesser extent
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interfered with BV2 cells—dependent effects (Fig. 3f). Concor-
dantly, the antibody against CSF2Rα decreased the invasiveness of
glioma cells, which was induced by the co-culture with BV2 cells;
an isotype control antibody had a negligible effect.
Tumour-infiltrating microglia and macrophages display the pro-
tumorigenic, immunosuppressive phenotype in gliomas.1 We
studied the expression of genes recognised as markers of pro-
tumorigenic (IL10, MYC) and inflammatory (IRF7, IL1B) phenotypes
in primary human microglia cultures treated with LN18 and U87
glioma conditioned medium (GCM). GCM from control LN18 and
U87 cells (shNeg) induced IL10 and MYC expression in human
microglia, while knockdown of CSF2 in glioma cells reverted IL10
mRNA to the basal levels. Moreover, we observed upregulation of
IRF7 mRNA and Il1b mRNA in human microglia upon stimulation
with CSF2-depleted LN18 or U87 glioma cells, respectively, relative
to treatment with shNeg-conditioned medium (Fig. S2). This
indicates a shift of microglia from anti- to pro-inflammatory
phenotype in the absence of tumour-derived CSF2.
Tumour-derived CSF2 controls recruitment of microglia and
macrophages and contributes to tumour progression
To study the impact of tumour-derived CSF2 on the brain
microenvironment, we encapsulated human U87 and LN18 glioma
cells into hollow fibres (HF) and transplanted them into the brains
of immunocompetent mice. Hollow fibres were permeable to
tumour-derived soluble factors, but prevented direct interactions
between tumour cells and microenvironment, and thus precluded
the immune system activity towards foreign cells.33 HFs filled with
control (shNeg) and CSF2-depleted (shCSF2) glioma cells were
implanted into either hemisphere of the same mouse brain. After
2 weeks, the histological analyses of the implants showed that the
outer membranes of the shNeg LN18 and shNeg U87 fibres were
surrounded by Iba1+ cells, while significantly less cells migrated
towards the HF with CSF2-depleted LN18 and U87 glioma cells.
Density of Iba1+ cells in the areas surrounding the encapsulated
CSF2-depleted LN18 or U87 gliomas was, respectively, 2.8-fold
(Fig. 4a) or 1.4-fold (Fig. S3) lower than around the shNeg-
containing HF. There was no change in infiltrating GFAP-positive
astrocytes surrounding glioma-filled fibres (Fig. 4 and Fig. S3).
Next, control (shNeg) and CSF2-depleted (shCSF2) LN18 glioma
cells were intra-cranially implanted into striata of athymic mice.
Human cells were detected by staining for human PCNA
(proliferating cell nuclear antigen). Growth of shCSF2 tumours
was significantly reduced relative to controls (shNeg), as shown by
anti-PCNA immunofluorescence (Fig. 5a) and histologic evaluation
of the tumour volume (Fig. 5b). Survival of mice with CSF2-
depleted gliomas was considerably prolonged (Fig. 5c). Intra-
tumour infiltration of microglia and macrophages, evaluated with
Iba1 staining, was decreased in CSF2-depleted LN18 gliomas
compared to control shNeg tumours (Fig. 5d, e).
CSF1 and its receptor CSF-1R support proliferation and survival
of mononuclear phagocytes through the DAP12-β-catenin axis,
which controls the expression of survival genes.34 We explored if
tumour-derived CSF2 is important for survival of infiltrating
microglia and macrophages by double staining of the glioma-
bearing brain sections for Iba1 and TUNEL (Terminal dUTP nick-
end labelling of DNA) that allows to identify DNA fragmentation
and stains apoptotic cells. Confocal microscopy analysis revealed
significant increase of the number of Iba1+ TUNEL+ cells in shCSF2
gliomas as compared to shNeg tumours (Fig. 6a, b). This
demonstrates that glioma-derived CSF2 is important in supporting
both accumulation and survival of microglia and macrophages.
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DISCUSSION
Tumour-infiltrating microglia and macrophages support glioma
progression via multiple mechanisms and make a plausible target
in designing new therapeutic strategies.5,7,11,12 Studies with CSF-1R
inhibitors in transgenic or experimental murine gliomas point to a
role of CSF1 signalling in mediating glioma–microenvironment
interactions.16,17 However, CSF1 mRNA levels were not elevated in
GBMs in comparison to normal brains or benign astrocytomas.6
Moreover, we found that CSF2 mRNA is elevated in a subset of
GBMs, particularly in the mesenchymal GBM subtype being the most
aggressive. Correspondingly, GBMs with high CSF2 mRNA levels
have upregulated expression of immune/wound healing genes,
which indicates extensive microglia and macrophage infiltration.
We demonstrate that CSF2/GM-CSF (produced by human LN18
and U87 glioma cells) stimulates microglia to enhance tumour
invasion. CSF2 knockdown in glioma cells or interference with
CSF2 signalling using anti-CSF2 or anti-CSF2Rα antibodies
significantly reduced microglia-dependent invasion in vitro.
CSF2 secreted by glioma cells stimulated microglia accumulation
around of LN18 and U87 gliomas encapsulated in hollow fibres
in vivo. CSF2-depleted LN18 gliomas, when growing in nude mice,
were less infiltrated by Iba+ cells and formed smaller tumours as
compared to gliomas derived from shNeg cells. Moreover, mice
harbouring shCSF2 gliomas lived longer than those with control
tumours. Interestingly, knockdown of CSF2 in glioma cells did not
affect astrocyte activation and accumulation.
In fact, both glioma cells and immune cells are able to produce
and respond to CSF2/GMCSF.26,27,35,36 This cytokine was shown to
increase glioma migration and protect certain glioma cells from
apoptosis.26,27 CSF2/GMCSF may stimulate production of other
growth factors (nerve growth factor, granulocyte colony stimulat-
ing factor, vascular endothelial growth factor). Receptors for those
cytokines are expressed on glioma cells, endothelial and stromal
cells, and their interplay may contribute to formation of new
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blood vessels.35,36 We found fragmented DNA in some Iba1+ cells
in shCSF2 gliomas, indicating ongoing cell death. This observation
may indicate a supportive role of granulocyte macrophage colony
stimulating factor for survival of microglia and macrophages in the
tumour microenvironment. CSF1/M-CSF signalling maintains
proliferation and survival of monocytes through DAP12-β-
catenin signalling pathway,34 and CSF2/GMCSF has been shown
to regulate β-catenin signalling during myeloid lineage differ-
entiation,37 and contribute to the survival of infiltrating monocytes
in rat gliomas.38
We show that LN18 and U87 glioma polarise primary human
microglia cultures towards the pro-tumorigenic, immunosuppres-
sive phenotype (up-regulation of IL10, MYC) in vitro. CSF2
depletion from both LN18 and U87 glioma cells blocked up-
regulation of the anti-inflammatory IL10 expression and led to
induction of IRF7 and IL1β mRNA levels in stimulated microglia.
This may indicate a shift towards a pro-tumorigenic phenotype
upon glioma cells-derived CSF2. However, due to a small set of
tested genes, at this stage it is an assumption. Previous studies
demonstrated that in vitro CSF2-treated monocytes differentiate
into inflammatory macrophages, whereas CSF1-treated mono-
cytes acquire an anti-inflammatory phenotype.39–41 This distinct
response is attributed to different mediators: the interferon
regulatory factor (IRF) 5 is an inducer of inflammation-related
genes,42 whereas IRF4 and Klf4 control anti-inflammatory macro-
phage polarisation genes.43,44 Interestingly, in human monocytes,
IRF4 is more robustly upregulated than IRF5 after CSF2 addition.45
The response to CSF2 in the tumour microenvironment is more
complex and may be affected by other cytokines or tumour-
derived metabolites. For example, in the presence of lactate,
which is abundant in the tumour milieu as of Warburg effect,
CSF2-activated macrophages cannot produce pro-inflammatory
cytokines, but rather, generate vast quantities of anti-
inflammatory cytokines.46 Extensive use of CSF2 as an adjuvant
to anti-cancer vaccines may be thus controversial, unless suited to
cancer-specific conditions.47
In GBMs, up-regulated CSF2 production, as indicated herein and
in previous studies, promotes immunosuppressive activity of
tumour-infiltrating myeloid cells.38,48 Moreover, CSF2 contributes
to systemic immune deficits due to generation of neutrophilia and
lymphopenia in GBM patients.48,49 Immunosuppressive myeloid
cells in glioma microenvironment constitute a barrier to emerging
immunotherapies. Recent single-cell RNAseq data, including ours,
suggest that this immunosuppressive population in both experi-
mental and human gliomas originates both from blood-derived
monocytes and brain-resident microglia.50,51 Monocytes, recruited
into the tumour by chemotaxis, upregulate the expression of
immunosuppressive cytokines and carry on programmed death
ligand 1 (PD-L1), a suppressor of an adaptive immune system.50,51
It would be of interest to analyse effectiveness of the combined
anti-GBM treatment using immune checkpoint PD-1/PD-L1 block-
ade with alleviation of CSF2-mediated recruitment and immuno-
suppressive polarisation of myeloid cells.
Taken together, our results point to an important role of
tumour-derived CSF2 in the pathology of human gliomas. We
demonstrated the up-regulated expression of CSF2 in TCGA data
set herein and in GBM biopsies.6 The role of CSF2 in the tumour-
driven accumulation of microglia and macrophages and its
contribution to glioma progression and immunosuppression
suggest that CSF2 signalling might be a novel target for
glioblastoma therapy. The results could pave a way to new
modalities, in which targeting myeloid cells is combined with
immune check-point blockade immunotherapies.
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